Navigating healthcare costs can be confusing, especially when it comes to diagnostic testing. If you’re considering Quest Diagnostics for hereditary cancer solutions and wondering about payment methods, you might be asking, “Why does Quest Diagnostics not accept Care Credit?” While specific payment policies can vary and may not be explicitly stated as excluding Care Credit, it’s helpful to understand the payment options Quest Diagnostics does prioritize, and why focusing on these might be more beneficial for patients concerned about costs.
It’s important to recognize that healthcare providers and diagnostic services like Quest Diagnostics have various financial systems in place. Instead of focusing on external credit options like Care Credit, Quest Diagnostics emphasizes programs designed to directly assist patients with the costs of essential testing. Their primary goal is to ensure that financial concerns don’t prevent individuals from accessing crucial hereditary cancer screenings.
Quest Diagnostics offers a dedicated Financial Assistance Program to make these vital tests more accessible. This program is a cornerstone of their commitment to affordable healthcare. For patients who qualify based on income – specifically those with a household income at or below 400% of the federal poverty level – out-of-pocket expenses can be capped at just $200 for eligible hereditary cancer tests. For those facing even greater financial hardship, such as uninsured or underinsured individuals with incomes at or below the federal poverty level, testing may be provided at no cost.
Furthermore, understanding the types of tests covered under the Financial Assistance Program highlights Quest Diagnostics’ dedication to comprehensive care. The program applies to a wide range of critical hereditary cancer tests, including:
- Comprehensive Hereditary Cancer Panel
- Guideline-Based Hereditary Cancer Panel
- Hereditary Breast Cancer Panel
- Hereditary Colorectal Cancer Panel
- BRCA Panel and more.
This broad coverage demonstrates their commitment to offering financial solutions across a spectrum of necessary diagnostic services. In addition to these programs, Quest Diagnostics also provides flexible payment plans, including 0% financing for 12-month periods for patients needing further assistance. This proactive approach to financial accessibility suggests that while external credit options like Care Credit might not be their focus, Quest Diagnostics offers internal solutions that are potentially more tailored and beneficial for their patients seeking hereditary cancer testing.
For anyone seeking clarity on payment options or wishing to explore the Financial Assistance Program in detail, reaching out directly to Quest Diagnostics is the best course of action. They can be contacted at 1.866.GENE.INFO (1.866.436.3463) to discuss individual circumstances and available resources, ensuring that financial concerns are addressed effectively and that patients can access the hereditary cancer testing they need.
